List of Therapeutic Companies in Florida - 113

Adolore Biotherapeutics, Inc., is a biotechnology company focused on developing novel therapies for the treatment of chronic pain and other pain and nervous system conditions or disorders. Our best-in-class lead programs are long-acting locally acting gene-therapies that are opioid-free Disease Modifying Anti-Pain therapies (DMAPs) for the treatment of a variety of chronic pain indications. The Company’s two current CA8* gene therapy programs are in preclinical development for treatment of patients suffering from erythromelalgia, a life-long heritable chronic pain condition representing an orphan drug disease with no approved therapy, and chronic osteoarthritis knee pain, affecting a large number of patients that is often treated with opioids due to the lack of alternatives, thus contributing to the ongoing opioid crisis.

ADvantage Therapeutics - Headquartered in the Wynwood neighborhood in Miami, ADvantage Therapeutics is developing therapies to treat neurodegenerative conditions with a central focus on Alzheimer’s disease. The Company’s lead compound AD04™ is an injectable therapy in the process of entering into a confirmatory Phase 2b clinical trials in Europe to evaluate safety and efficacy of the product in early Alzheimer’s Disease. The Company believes that AD04™ may act as an immunomodulator, stimulating and regulating the immune system to reduce AD pathology, rather than limiting therapy to the aggregation of the proteins present once pathology is present. The Company is also exploring additional approaches to mitigating neurodegenerative disease, which it believes will eventually have an overall impact on longevity.

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications. The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years. AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products Find AGTC on YouTube at goo.gl/sMdJqX.

AIM ImmunoTech Inc., an immuno-pharma company headquartered in Ocala, Florida, is focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases. AIM ImmunoTech’s flagship products include Ampligen® (Rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon N Injection® (Interferon Alfa-N3). Ampligen® represents an RNA being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen® is also being evaluated for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Alferon N Injection® is approved for a category of STD infection and patients that are intolerant to recombinant interferon in Argentina. Alferon is the only natural-source, multi-species alpha interferon currently approved for sale in the U.S. for the intralesional treatment of refractory (resistant to other treatment) or recurring external Condylomata Acuminata/genital warts (GW) in patients 18 years of age or older. We operate a 30,000-square-foot facility in New Brunswick, NJ to produce Ampligen® and Alferon®. We are committed to a focused business plan oriented toward finding senior co-development partners with the capital and expertise needed to commercialize the many potential therapeutic aspects of Ampligen® and our FDA-approved drug Alferon® N.

At Allay Health and Wellness, we offer a new approach to health and wellness by focusing on the individual as a whole. Picking a provider is a crucial step and Allay is approaching 3000 Infusions! Clinical Trials are showing great success in helping those with Alzheimer's, Parkinson's, addiction, and multiple ailments. We want to focus on the mind, body, and soul so that you can continue to have the best quality of life. We believe that by taking care of yourself, you will have the ability to make better decisions, process information better, and have the tools necessary to deal with physical and emotion pain. We believe that our low dose approach to ketamine infusion therapy, teamed with Cognitive Behavioral Therapy will help you to take care of yourself. Our team of licensed medical providers and mental health clinicians will work with you to develop a treatment plan that best suits your needs. We want to be the starting point of your recovery.

Allodynic Therapeutics is a clinical-stage biopharma company engaged in developing naltrexone-acetaminophen (ALLOD-2) as an oral investigational product for the acute treatment of migraine. Both naltrexone and acetaminophen individually can simultaneously reduce physical and emotional pain, potentially enhancing treatment outcomes. Naltrexone-acetaminophen U.S. patents extend to 2037.

Ambulero is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease. We are a platform company that can deliver the adhesion molecule E-selectin using different cell and synthetic vector technologies. We work on rare vascular diseases as well as more common indications effecting large patient populations.

Amend Surgical leads the biopharmaceutical industry in promoting development of bone healing with NanoFuse, a bone graft substitute and bone void filler.

Archer Pharmaceuticals, Inc. (Archer) was founded in 2008 and specializes in drug discovery for Alzheimer’s disease and other dementias.

Asana Medical focuses on the development and commercialization of medical devices for gastrointestinal applications.

At Asha Therapeutics, we are leveraging our expertise in computational chemistry and neurobiology to develop novel therapeutics that enable the re-engineering and restoration of neurological function. Our lead assets demonstrate efficacy in both human cells and murine models of neurodegenerative diseases including Parkinson’s Disease, Stroke, Alzheimer’s Disease, ALS, and Multiple System Atrophy.

Aurita Corp is a synthetic biology startup that creates a platform for 3D bioscience intended to provide personalized medicine and diagnostics, therapeutic solutions, and cell culture tools.

Avenue Therapeutics is a specialty pharmaceutical company whose mission is to develop IV tramadol, a potential alternative that could reduce the use of conventional opioids, for patients suffering from acute pain in the U.S. Avenue is headquartered in New York City and was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). FBIO owns a controlling number of voting shares of ATXI. Invagen entered an agreement to purchase ATXI if certain conditions are met, including approval of IV tramadol before April 30, 2021, but Invagen has indicated that due to the Covid epidemic, it can terminate its purchase agreement to acquire ATXI.

Axogen is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or discontinuity to peripheral nerves by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Axogen’s comprehensive portfolio of products focuses on helping patients touch, run, feel, kiss, smile and hug—some of the many things healthy peripheral nerves allow us to do.

We're a leading global eye health organization that is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Our comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, we have a significant global research and development, manufacturing and commercial footprint with more than 12,000 employees and a presence in nearly 100 countries.

Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to restore and improve the vision of patients with a range of prevalent and rare retinal diseases that result in blindness. The Company has an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP), as well as two preclinical programs, one targeting dry age-related macular degeneration (AMD) and another in-licensed from the University of Oxford targeting cone-rod dystrophy (CRD), an inherited retinal disease. Lead development candidate AGTC-501, is a gene therapy program in Phase II clinical trials for the treatment of XLRP, an inherited monogenic recessive disorder that causes progressive vision loss in boys and young men. XLRP is predominantly caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene. AGTC-501 expresses the full length RPGR protein, thereby addressing the full complement of photoreceptor damage caused by XLRP, including both rod and cone loss. Beacon Therapeutics also has access to a target generation technology platform that will identify, screen, and search secreted proteins in the ophthalmology space. The Company is supported by funds from Syncona and additional investors including Oxford Science Enterprises.

BioCurity Pharmaceuticals Inc. (“BioCurity”), is a biopharmaceutical company with a mission to positively transform radiation therapy for cancer patients, by addressing the global unmet need for an effective treatment to prevent toxicity from radiation therapy (radiation dermatitis). Approximately 6 million of the 18 million people who will be diagnosed with cancer every year, will receive radiation treatment. The lack of an effective treatment for the adverse side effects associated with radiation therapy represents a substantial market opportunity, but most importantly, a chance to help better the quality of life for cancer survivors around the world. BioCurity’s patented technologies and drugs in their pipeline have the potential to significantly reduce radiation toxicity for newly diagnosed patients as well as the millions of cancer patients who continue to receive radiation as a part of their ongoing treatment for cancer.

Cadrenal Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, an oral therapeutic designed to be a superior and safer Vitamin K antagonist (VKA) anticoagulant for patients with implanted cardiac devices or rare cardiovascular (CV) conditions. Cadrenal strives to improve outcomes and reduce adverse events for these patients such as strokes, heart attacks, bleeds, and deaths. These patients also lack approved chronic anticoagulation options besides warfarin, well-known for its serious side effects and frequent drug-drug interactions, resulting in complicated treatment management. Cadrenal’s drug candidate, tecarfarin, is a new VKA anticoagulant with extensive clinical data showing it is potentially superior and safer than warfarin, resulting in fewer adverse events. Tecarfarin is metabolized via a different pathway than warfarin and data demonstrate that its efficacy is unaffected by common drug-drug interactions or kidney impairment, which are common in these patients. Phase 2/3 clinical trials show that tecarfarin may offer more stability and time in therapeutic range (TTR) that inversely correlates with major events. Tecarfarin received an orphan drug designation for advanced heart failure patients with left ventricular assist devices (LVADs) as well as both orphan drug and fast-track status for end-stage kidney disease (ESKD) patients with atrial fibrillation. Cadrenal is opportunistically pursuing pivotal clinical trials with LVAD patients along with clinical and commercial partnership opportunities to advance tecarfarin. The company’s plans also include studying patients with mechanical heart valves who experience anticoagulation difficulties because of genetic warfarin resistance, polypharmacy, or kidney impairment. For more information, please visit: www.cadrenal.com.

Medical Jane is an online resource that allows users to learn more about the medicinal benefits of cannabis, review different strains of cannabis and dispensaries, and get involved as an activist. The site's tools help patients manage their health, find quality dispensaries, and determine which cannabis strain is appropriate for their particular ailment. Medical Jane strives to be a trusted, independent platform that connects a dedicated following of medical marijuana patients, caregivers, and cannabis-activists alike. Learn more at www.medicaljane.com.

Cantex Pharmaceuticals, Inc. is a pharmaceutical company developing treatments of cancer, complications of COVID-19 infection, and pulmonary inflammatory diseases.

Catalyst is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases.

Cognigenics develops innovative RNA-based gene therapies targeting memory loss, cognitive decline, anxiety associated with mild cognitive impairment and other neurocognitive and neuropsychiatric disorders. Our intranasal delivery platform targets neuronal receptors in the brain involved in CNS disorders including anxiety, and Mild Cognitive Impairment.

Continuity Biosciences, LLC, is dedicated to developing and commercializing cutting-edge technologies for cell reprogramming, immune modulation, and ultra-long acting drug delivery. The company seeks to leverage the immense potential at the intersection of biopharmaceuticals and medical technologies, especially in creating combination products that can help realize the full potential of remarkable therapies. While our foundation is built on technologies licensed from Prof. Grattoni's pioneering research at the Houston Methodist Hospital, we plan to continuously expand our technology portfolio to provide our partners with diverse options for their product presentation strategies.

Coquí RadioPharmaceuticals is a radiopharmaceuticals company focused on creating a scalable and reliable domestic supply of Mo-99 to provide low-cost diagnostics and treatments to patients.

Cordis is a medical devices company that specializes in cardiology equipment and healthcare technology.

CTM is dedicated to developing surgical implants to help physicians treat post-operative biologic issues that are beyond their control.

We Focus on Identifying, Acquiring and Developing Disease-Modifying Therapeutic Drug Candidates with Rare Disease Indications

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.gov NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is conducting a Phase 2b clinical trial using Trappsol® Cyclo™ intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the Company’s website: www.cyclotherapeutics.com.

Cytonics is a research and development company dedicated to discovering and developing therapeutics based on the protease inhibitor Alpha2 Macroglobulin (A2M). Theyhave discovered a unique “bio-marker” that can assist physicians in improving patient outcomes by pinpointing the source of orthopedic pain. We are also developing a range of therapeutic products for the treatment of painful osteoarthritis, back, and joint pain.

Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive Flex-NK™ bispecific antibody and iPSC-derived, TALEN® gene-edited NK-cell platforms. FLEX-NK™ bispecific antibodies are built on a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using Cytovia's proprietary Flex-NK™ technology. The company is also developing three types of iPSC-derived NK (or iNK) cells: unedited iNK cells, TALEN® gene-edited iNK cells with improved function and persistence, and TALEN® gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. ​ These two technology platforms are being used to develop treatment of patients with solid tumors such as hepatocellular carcinoma (HCC) and glioblastoma as well as hematological malignancies such as relapsed multiple myeloma. Clinical studies are expected to initiate in 2023.

DemeRx is a clinical stage pharmaceutical development company advancing drug candidates as therapies for addiction.

Dyadic International, Inc. (Nasdaq: DYAI) - We are a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and cost to patients and the healthcare system - but most importantly to save lives.

Emmune, Inc. is a start-up biotechnology company that has a novel approach for treating and preventing HIV infection. We engineered a synthetic antibody from the receptors that HIV uses to infect T cells, CD4 and CCR5. Because this synthetic antibody, known as “eCD4-Ig,” is built from the viral receptor and co-receptor, it recognizes 100% of HIV-1 isolates. A single intramuscular inoculation with an AAV vector expressing eCD4-Ig protected monkeys from multiple intravenous challenges with live virus.

Enalare Therapeutics Inc. is a clinical stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from life threatening acute respiratory and critical care conditions, including respiratory depression caused by drug overdose, post-surgery, and other conditions. The Company is planning to initiate pivotal studies for its lead compound ENA-001 in the near term.

Entero Therapeutics, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company’s programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. For more information visit www.enterothera.com.  Entero Therapeutics is currently advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its two proprietary technologies – niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Entero’s niclosamide portfolio is led by three clinical programs: FW-COV, for COVID-19 gastrointestinal infections; FW-UP, for ulcerative proctitis (UP) and ulcerative proctosigmoiditis; and FW-ICI-AC, for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-associated colitis and diarrhea in advanced oncology patients. Two additional formulations of niclosamide, FW-UC (ulcerative colitis) and FW-CD (Crohn’s disease) are expected to enter the clinic in 2022 and 2023, respectively. Entero is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis. The Company is headquartered in Boca Raton, Florida with clinical operations in Hayward, California. For more information visit www.firstwavebio.com.

EriVan Bio is a biotechnology company that focuses on innovating and delivering products and services related to exosome technology for molecular and cell biology research, regenerative medicine, and drug delivery.

Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases. Expansion has assembled the intellectual property, know-how, and proprietary enabling technologies and tools necessary to facilitate the creation of potent and specific small molecule binders of RNA. Through this unique platform, Expansion is building a portfolio of novel RNA-targeted drug candidates with activity across a broad number of disease indications. The company’s initial development focus is on therapies for patients with expansion repeat diseases who currently have limited and unsatisfactory treatment options. Expansion is based in Jupiter, Florida

EXUMA Biotech is a clinical-stage biotechnology company committed to bringing to market cell & gene therapies for the treatment of cancer. Founded in 2015, The company has rapidly built its core technologies and a growing global presence with operations in China (Shanghai and Shenzhen), Grand Cayman, and headquarters in West Palm Beach, FL.

Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue. The company has seven marketed prescription pharmaceutical products and over 20 programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Fred Hutchinson Cancer Center, Nationwide Children’s Hospital and Sentynl.

Gibson Oncology is developing a novel class of proprietary drug candidates currently in clinical trials for the treatment of difficult-to-treat tumors. Our product candidates are first-in-class based upon dual activity at C-MYC and Topo-1 which will improve safety and efficacy and offer future approaches for treating several cancers. There are currently five (5) ongoing clinical studies funded by the National Institutes of Health in patients with solid tumors and lymphomas. Finally, Gibson has developed proprietary second-generation product candidates expanding modes of delivery and treatment approaches in both pediatric and adult populations.

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company’s lead product include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

HDL Therapeutics is a clinical-stage company that researches, develops and commercializes therapeutics for the treatment of heart-related problems.

Molecular Diagnostics

Hesperos, Inc. is accelerating drug discovery by providing safety and efficacy testing of chemicals and novel therapeutics for the pharmaceutical, cosmetic, and food industries using its patented, Human-on-a-Chip platform. Bringing together biologists, surface chemists, and engineers, our team is producing some of the world's most advanced organs-on-a-chip platforms. From gene expression to electrophysiology, we recreate key components of organs in an interconnected, functional system. Chemically patterned microchips enable real-time, non-invasive monitoring of organ function where we use sophisticated measurement techniques to detect minute changes. This breakthrough technology enables unprecedented visibility into specific disease states and how the human body will respond to treatment - something that previously required costly animal testing and human trials to determine. The functional, interconnected, human in vitro platform, provides preclinical insight into the efficacy and toxicity of novel therapeutics. Ultimately, Hesperos’ Human-on-a-Chip is reducing the need for animal testing in drug discovery while enabling research into rare diseases previously considered untreatable.

I train all of the company's pharmaceutical sales representatives in Hill's line of prescription products for dermatological diseases.

ILiAD Biotechnologies is utilizing its B-Tech vector platform to develop next generation vaccines to eradicate infectious diseases and improve lives. Its lead candidate, BPZE1, which has completed Phase 2 clinical trials, is the most advanced next generation vaccine for the prevention of whooping cough, a serious illness caused by Bordetella pertussis.

ImmunSYS is a clinical stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products to improve the lives of patients with late-stage metastatic prostate cancer and other metastatic solid tumor cancers. ImmunSYS is at the forefront of an entirely new approach to treating cancer. Our platform therapy has been shown to be effective in some metastatic cancers and may have wide applications as a cancer treatment for several solid tumor cancers, with the potential for cure in some patients. The company’s revolutionary therapy, YourVaccx™ utilizes a novel combination of controlled cell lysis and a triple-component immunotherapeutic drug. This new immunotherapy focused therapy is designed to empower the immune system to recognize and selectively attack cancer cells throughout the body. The company is initially developing the new cancer therapy for the treatment of metastatic prostate cancer, with a pipeline of additional development programs for other solid tumor cancers. Our proprietary therapy was conceived by the focal prostate cancer therapy pioneer and inventor of the male lumpectomy, Gary Onik, M.D. He is not only the inventor, but also a patient. Dr. Onik developed aggressive metastatic prostate cancer in 2018 and received his own therapy. He had a complete response and remains disease-free to date. ImmunSYS is committed to bringing life-changing treatments to cancer patients by bringing the tumor to the immune system to fight cancer in a new way. We believe our new YourVaccx™ therapy has the potential to offer cancer patients substantial benefits over the existing standard of care, including the potential for cure in some patients.

InflammX Therapeutics, Inc. is targeting inflammasome mediated and recycling inflammation, and providing a therapeutic effect to both eyes simultaneously. They have a pipeline focused on ophthalmic treatments and have submitted an IND amendment to enable clinical studies with orally dosed Xiflam, their NLRP3 inflammasome targeting program in retinal and kidney disease.

INmune Bio Inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease. Media coverage provided for informational purposes only and third party links provided as a resource. INmune Bio does not control the content of third parties. XPro1595, Quellor, LIVNate, INB03, INKmune and other drug candidates, have not yet been shown to be safe or effective, and has not been approved by any regulatory body.

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries and regions. With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. Santen Pharmaceutical Official Social Media Global Terms of Use​ https://www.santen.com/en/legal/

At Pacira Biosciences, Inc., we are driving innovation to provide ways to manage pain safely and effectively. iovera° is a patented, 510(k)-cleared medical device, which uses targeted cryoanalgesia for immediate and long-lasting pain relief. iovera° treats peripheral nerves to temporarily stop pain signals for up to 90 days and provides pain relief until the nerve regenerates and nerve signaling is restored through an innovative handheld design. The iovera° system is used to destroy tissue during surgical procedures by applying freezing cold. It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. It is also indicated for the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days. The iovera° system is not indicated for treatment of central nervous system tissue. iovera° should not be used for people with: cryoglobulinemia, paroxysmal cold hemoglobinuria, cold urticaria, Raynaud's disease, open and/or infected wounds at or near treatment site. Patients treated with iovera° (a needle-based therapy) may have certain reactions, including but not limited to bruising, swelling, inflammation and/or redness, local pain and/or tenderness, altered feeling at application site. Proper iovera° use (see User Guide) can help reduce or prevent these reactions: in treatment area(s) – skin damage from being exposed to cold/heat, skin darkening/lightening, skin dimples; outside treatment area(s) – muscles may not work/move normally. Adverse event reporting: email drugsafety@pacira.com or call 1-855-793-9727. Product quality complaints: email drugsafety@pacira.com or call 1-800-442-0989. Please don't report such information through this or other social media pages owned by Pacira Biosciences, Inc. If you do report through this page, Pacira reserves the right to contact you for information.

iTolerance is a privately held regenerative medicine company enabling tissue, organoid or cell therapy without the need for life-long immunosuppression. Leveraging our proprietary technology platform, iTOL-100, we are advancing a pipeline of programs using both allogenic pancreatic islets and stem-cells that have the potential to cure diseases. Our lead program, iTOL-101 is being developed for Type 1 Diabetes and in a preclinical non-human primate study, pancreatic islet cells co-implanted with iTOL-101 exhibited long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression. Our follow-on candidate, iTOL-102 is leveraging significant advancements in stem cells, which allows a potentially inexhaustible supply of insulin-producing cells for use in Type 1 Diabetes. Additionally, the Company is developing iTOL-201 for liver failure and iTOL-301 as a potential regenerative protein and cell therapy that leverages stem cell sources to produce proteins or hormones in the body in conditions of high unmet need.

Jupiter Neurosciences, Inc. is a clinical-stage drug platform company focused on treating neuroinflammation. Our mission is to make a significant impact for patients and society through a safe and oral medication for Alzheimer’s disease and for people with rare diseases.

Kaida BioPharma was founded on the research principles and clinical evidence of G129R, a growth hormone antagonist that has shown to induce programmed cell death (autophagy) in gynecologic tumors. Our collaboration with Dr. John Langenheim, professor at Thomas Jefferson University and Dr. Anil Sood at MD Anderson, who have published extensive research on G129R, has provided solutions we intend to bring to the clinic. At Kaida, we are dedicated to providing a new hope for patients with treatment-resistant gynecological cancers. Our mission is to develop innovative therapies that target the specific needs of those patients, offering a medical treatment that can make a significant difference. For more information, please visit kaida-biopharma.com.

We are a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Our lead investigational product is Lomecel-B™, which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult diseases and conditions associated with aging. We are currently conducting Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS), which is the current exception to our focus on aging. Our mission is to advance Lomecel-B™ and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Our philosophy is that healthy aging can be improved through regenerative medicine approaches. Life expectancy has substantially increased over the past century as a result of medical and public health advancements. However, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging – a period known as healthspan. As we age, we experience a profound decline, in both number and function, in our own MSCs, a decrease in immune system function, decline in blood vessel functioning, chronic inflammation and other issues. Our clinical data suggest that Lomecel-B™ addresses these conditions through multiple mechanisms of action, or MOAs, that simultaneously target key aging-related processes.

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 22,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

M2Gen® is a health informatics solutions company focused on accelerating the discovery, development and delivery of personalized medicine.

Marizyme, Inc. is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical technologies that improve patient health outcomes.

MMI ia an incubated entity in Mergenet Solutions, Inc.

MLM Biologics Inc. (MLM) is a Delaware C-Corp company founded on the modern interpretation of Gandhian Economic Principle of "More for Less for Many". The company utilizes their expertise in chemistry and biology of scaffolds, and a proprietary processing platform, to deliver evidence-based solutions for musculoskeletal and wound care problems.

Myosin Therapeutics - The mission of Myosin Therapeutics, Inc. is to improve health outcomes through the development of novel pharmacotherapies targeting members of the myosin family of molecular motors. Myosin Therapeutics is positioned as the first nanomotor platform company focused on oncology, with a proprietary nMotor system for drug discovery. nMotor is a full screening platform from HTS to validation and target selectivity profiling, enabling Myosin to develop a robust pipeline of oncology therapeutics. Myosin has used nMotor to develop a unique therapeutic to improve outcomes in Glioblastoma (GBM), a critical unmet need with a conservative estimated serviceable market of at least 10,000 cases yearly in the US alone. Additionally, Myosin is developing a unique neurotherapeutic to prevent relapse in METH use disorder, another critical unmet need. METH use disorder is a chronic disorder for which there are currently no FDA-approved medications. More broadly, preclinical studies indicate that first-in-class pharmacotherapeutics targeting NMII have value in many applications, including other substance use disorders, cancer, neural regeneration and infectious diseases. Further, approval of a clinically safe NMII inhibitor will enable scientific advancements into the study of NMII’s contribution to human physiology, such as learning and memory.

Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Leveraging its expertise in nanoparticle and fine-particle formulations, which can specifically be used to improve hard-to-deliver BCS category II and IV drugs, Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability.

NAYA Biosciences is building a group of companies leveraging the next generation of biotechnologies to increase patient access to life-transforming treatments in oncology, fertility, and regenerative medicine. Our unique capabilities in biology, cell and gene therapy, and artificial intelligence provide a synergistic platform for the accelerated clinical development and commercialization of these breakthrough treatments.

Neobiosis, LLC is a privately owned, clinical stage, biomedical contract development and manufacturing organization (CDMO) with two production facilities in downtown Gainesville and a Research & Development laboratory located within the Sid Martin UF Innovate biotechnology Institute in Alachua, FL. The focus of Neobiosis is the isolation of tissues, cells and extracellular vesicles (EVs), with medicinal potential, from donated perinatal (birth) tissues, including umbilical cord, umbilical cord blood and amniotic fluid. The name Neobiosis ("new life") is derived from a series of experiments called Parabiosis ("living together") where it was discovered that tissues, cells and EVs from a young donor could be used to promote the healing of older individuals. Neobiosis produces innovative products from healthy, full-term births, for client organizations who wish to take biomedical products though FDA-approved clinical trials for commercialization in a global market. Neobiosis is also committed to advancing an in-house pipeline of intellectual property and biologicals for use in anti-aging and regenerative medicine.

Nonagen Bioscience is a biotechnology company that specializes in developing first-in-class diagnostics for early detection and prediction of human cancers.

Noven Pharmaceuticals, Inc. is a dynamic specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products. We are committed to developing and offering pharmaceutical products that meaningfully benefit patients, with a commitment to advancing patient care through transdermal drug delivery. Over 300 Noven colleagues are working to advance our business and benefit patients at locations in Miami, FL, Jersey City, NJ. We are a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., the world’s largest manufacturer of transdermal patches, and we serve as Hisamitsu's growth platform for U.S. prescription pharmaceuticals. Noven maintains state-of-the art, FDA-approved transdermal manufacturing facilities in Miami with capacity to produce several hundred million patches per year. These facilities are also approved by the U.S. DEA (Drug Enforcement Agency) for the production of controlled substances.

Nuovo Biologics, LLC is a Florida based biotechnology company dedicated to research and development of the most innovative, safe and efficacious products such as drugs, biologicals, and supplements to best support and maximize animal health. Though the Company is focused on the animal market, it is performing translational research on products that can be applied to the human market. Nuovo Biologics, LLC is dedicated to provide information sharing, training and education for clinical research and new product development promoting animal health and advocacy among all animal industry stakeholders.

Oncogenuity is a biopharmaceutical company committed to developing and commercializing new treatments for genetically driven diseases. Our lead asset targets the KRAS mutation G12D, which plays a significant role in pancreatic and colorectal cancers, as well as other “untreatable” cancers of considerable unmet need. Our core technology focuses on the delivery of PNA’s (peptide nucleic acids). The PNA acts as a targeting sequence for gene-silencing. These targeting sequences are interchangeable, and we plan to aggressively pursue both oncology and non-oncology genetic mutations where gene silencing can be effective. We are a partner of Fortress Biotech, and we have an exclusive licensing agreement with Columbia University to develop oligomers (ONCOlogues) that attack genetically driven diseases at the DNA level.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase IIb trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.

Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases, including those caused by coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics.

Orasis is reshaping vision possibilities. As agile partners to the eye care community, we see every day as an opportunity to disrupt conventional thinking in pursuit of vision without limitations. That is why we reimagined existing and well-studied molecules to create a unique prescription eye drop for presbyopia, QLOSI™.

Pacira BioSciences Inc. is a leading provider of non-opioid pain management and regenerative health solutions. We are dedicated to offering patients—and the clinicians who treat them—cutting-edge therapies to treat pain with the potential to reduce or eliminate the need for opioids. Founded in 2006 and headquartered in Tampa, FL, Pacira has offices in Parsippany, NJ as well as San Diego, CA. With more than 700 employees who share a passion for delivering improved patient care and reducing the need for opioids, Pacira is here to challenge and transform the way we think about – and treat – pain. We are committed to providing solutions that address unmet medical need and improve clinical results, and empowering patients and healthcare providers to choose non-opioid options. Our non-opioid product portfolio is aimed at opioid minimization, long-lasting pain control, and enhanced recovery. Find out why we aim for change at Pacira.com/commitments

Pasithea Therapeutics is a biotechnology company primarily focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders. We leverage our expertise in the fields of neuroscience, medicinal chemistry, and translational medicine to develop new molecular entities that target the pathophysiology underlying such diseases with the goal of bringing life-changing therapies to patients.

Ponce Therapeutics is developing a state-of-the-art biotechnology platform to restore the youthful balance of aged or “senescent” and young cells in your skin, targeting the senescent cells for elimination. This provides a “reboot” of your genetic program to turn the clock on your skin back to its youthful exuberance.

Profounda is a product-oriented, privately backed pharmaceutical company that aims to develop high quality specialty niche pharmaceutical products in both the branded and generic pharmaceutical markets. They are a team of industry experts whose objective is to focus on bringing high quality innovative options to patients being treated for various conditions at competitive prices in order to improve the lives of those that take our medication.

ProSolus Pharmaceuticals delivers sophisticated transdermal solutions customized to meet your needs and exceed your expectations. We formulate, develop, and manufacture high-barrier-to-entry transdermal drug delivery products in our state-of-the-art laboratories and manufacturing facility. Our patches are designed with the patient in mind. ProSolus Pharmaceuticals is an experienced partner with unrivaled transdermal prowess. Our experts are committed to delivering a customized experience every step of the way concept through completion. Whether you need formulation, development, and/or manufacturing support, we'll provide sophisticated solutions tailored to your needs. Our research and development team works collaboratively with strategic suppliers to create polymers and design combinations of excipients that improve the absorption of medications through the skin without having to resort to exotic permeation enhancers. Focused on what lies ahead, our team continues to explore methods to optimize transdermal drug delivery.

Psilera is a scientist-owned, woman-co-founded biotechnology research company with offices in New Jersey & Florida. Founded in 2019 by Jackie von Salm & Chris Witowski, Psilera is focused on early-stage drug discovery & development to provide new neurological therapeutics to the world. Psilera’s team is a dynamic collective of individuals with expertise in Synthetic & Computational Chemistry, Clinical Development, Operations, Business Development, Strategy, and People.

Biotechnology and drug discovery developing microbiome therapeutics and direct to consumer products. Early stage company with a completion of a licensing agreement, a consumer product BioEsse, (A Probiotic Essensce for the Skin), in production, and medical indication for NDA and integrated development plan in progress.

RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Aspiration System*, which includes a novel aspiration pump and catheters to allow rapid and consistent removal of blood clots from the brain. The RapidPulse logo and the word mark RapidPulseTM are trademarks of RapidPulse, Inc., and are the subject of applications pending in the United States and internationally. *The RapidPulseTM Aspiration System is not cleared for sale in the United States.

The Next Generation of Branched Aortic Stent Grafts A challenging frontier for aortic endovascular repair, complex aortic aneurysms are those involving the take-offs of major arterial branches or short landing zones. Through its patented technology, Red Vascular Technology meets this challenge with the next generation of non-modular branched endografts. Red Vascular Technology, LLC is currently involved in the development of minimally invasive techniques for the treatment of Aortic aneurysms of both the Abdominal and Thoracic Aorta which involve the major branch origins of these vessels. The current state of the art for the treatment of aneurysmal disease which effects the origins of the major branches is the use of "Fenestrations" including Periscope, or Chimney techniques of the endograft and construction of the device in-situ. All these techniques are Modular in nature which means that there are multiple parts of the endograft which must be deployed separately. This increases the complexity, complications and in general the outcomes of such devices. The Red Vascular Technology design and intellectual property allows the branch or branches to be non-modular and therefore the endograft is deployed in "one piece". This technology allows for less complications which in turn significantly increases patient safety and reduces cost.

Regenative Labs strives to process the highest quality human tissue allografts available in accordance with FDA and AATB requirements. Regenerative Medicine is a discipline that uses nature’s chemistry and biology to help the body repair itself.

Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada’s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit our website at: www.relmada.com

RemSleep creates products for sleep apnea and other sleep disorders. Now selling ResPlus CPAP machines. The soon to be FDA cleared, Deltawave device provides maximum airflow with minimum noise. it is the most comfortable interface on the market.

Resolve Therapeutics is a biotechnology company developing an exciting new biologic compound for the treatment of lupus that inhibits a key upstream step in the interferon cascade. The company is based on technology and compounds exclusively licensed from the University of Washington. The company will develop these compounds through early clinical testing and partner with a pharmaceutical company for late stage clinical development and commercialization.

Ridgeback Biotherapeutics is a biotechnology company focused on developing treatments and diagnostics for underserved patient populations primarily in pediatric orphan and emerging infectious diseases. The team at Ridgeback is dedicated to working toward finding life-saving and life changing solutions for patients and diseases that need champions. Headquartered in Miami, Florida, Ridgeback Biotherapeutics is a privately held, majority woman-owned biotechnology company; all funding for Ridgeback Biotherapeutics has originated from Wayne and Wendy Holman; two science driven individuals who invest in technologies that they believe will make the world a better place.

The Roskamp Institute is devoted to understanding causes of and finding treatments for neuropsychiatric and neurodegenerative disorders and addictions. Based in Sarasota, Florida, the Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer's disease. Headed by Dr. Michael Mullan and Dr. Fiona Crawford, the institute employs experienced and interdisciplinary scientists and technicians and houses state-of-the-art research labs and equipment to conduct scientific research. The quality of research performed at the institute reflects its motto: "Better science. Real discovery."

San Rocco Therapeutics is a biotechnology company with its primary focus on curative gene therapies for Sickle Cell Disease and Thalassemia

The Warrington College of Business is one of the nation’s premier business schools. As a part of a Research 1 institution, Warrington is dedicated to an extensive research agenda in addition to cultivating the young minds of our future leaders of industry. The College is comprised of the Heavener School of Business, the Fisher School of Accounting, and the Hough Graduate School of Business. Together, these three entities provide a full and enriching business education experience that not only prepares our students for business success, but enables them to thrive in the global economy. The University of Florida Warrington College of Business intends to educate, inform and provide updated information on Warrington's activities and news and to support and promote Warrington's objectives for these activities through its social media site. All Warrington comments are made by Warrington designees. This site is not a public forum. Social media users may share ideas through commentary that is consistent with and furthers the objectives of a Warrington post and the University of Florida Warrington College of Business reserves the right to remove any comments that do not fall within this purpose.

Singh Biotechnology (SBT) is a biotechnology organization that is in the business of discovering and developing unique and propriety therapeutic agents for the treatment of a variety of diseases (cancers, autoimmune, and ophthalmologic diseases) by leveraging our novel technology platform. At Singh Biotechnology we use our novel proprietary disruptive technology single domain antibody (sdAb) platform to create miniature antibodies that comprise solely of the variable region and therefore the sdAb is devoid of light chains. Using our proprietary technology we have engineered our sdAbs to be specific & bi-specific, with the ability to cross the cell membrane as well as the blood brain barrier (BBB) to specifically & selectively target intracellular proteins which play an important role in the pathogenesis of a variety of diseases. The United States Food and Drug Administration (FDA) granted orphan drug designation to Singh Biotechnology for its novel anti-STAT3 B VHH13 single domain antibody (sdAb) SBT-100: -For the treatment of pancreatic cancer on August 29th, 2016. -For the treatment of osteosarcoma on September 27th, 2017.

StemSynergy Therapeutics, Inc. (SSTI) is a biotechnology company focused on discovering drugs that target biomolecules and cellular processes fundamental to cancer. We target the cancer stem/initiating cell (CSC) populations, with the overall aim of eliminating tumor growth. We have two patents awarded and one patent pending for breakthrough technologies in modulating cancer stem cell pathways, such as those driven by Wnt, Notch, and Sonic Hedgehog (Shh) signaling. With a multi-pronged scientific approach and a number of agents targeting these pathways, SSTI is well positioned to address critical unmet needs in cancer treatment.

Stuart Therapeutics (Stuart) is a clinical stage biopharmaceutical company focused on the development of a unique tissue reparative platform for eye diseases called PolyColTM (PolyCol). PolyCol is a family of synthesized polypeptide sequences that are specifically designed to repair damaged extracellular matrix (ECM) helical collagen. Helical collagen structures play an important role in healthy tissues and they are damaged in chronic and acute/traumatic disease processes and injuries. Stuart was founded in 2018 to champion a new approach to the treatment of chronic diseases. Each of our founders has been affected directly or indirectly by chronic eye disease, and we have a passion for the pursuit of new and effective solutions for these indications. Stuart’s areas of interest are Dry Eye Disease, Glaucoma, and Dry Age-Related Macular Degeneration.

Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of an in situ platform therapy optimized for metastatic solid tumor cancers that aims to achieve high response rates with potentially improved survival. The company is currently developing SYNC-T, a personalized in situ therapy that combines partial tumor oncolysis and a multi-target biologic drug. The novel SYNC-T combination approach is designed to target multiple mechanisms of cancer, promoting in situ immune activation while battling immunosuppression. The goal is to activate T cells, enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in Phase 1 trials.

At Theragen, we strive to improve patient care and surgical fusion outcomes via non-invasive therapeutic electrical stimulation, advanced patient insights, and exceptional customer service. Theragen recently launched ActaStim-S, the smallest, most digitally capable, and data-driven non-invasive bone growth stimulator in over 2-decades. ActaStim-S assumed first-mover status by combining all-day wearability, proven capacitive coupling therapy, and automated daily clinical data capture to engage patients, enable compliance, and generate insight reports to inform clinicians when patients need guidance to stay on their healing journey.

TherapeuticsMD, Inc. is an innovative pharmaceutical company exclusively committed to advancing the health of women and championing awareness of their health care issues. We create products to address the unique changes and challenges women experience through every stage of their lives. With momentum fueled by the needs of our customers, we combine entrepreneurial spirit and clinical expertise to develop innovative solutions designed to go beyond what is presently available. This includes a variety of therapies in our pipeline, along with prescription prenatal vitamins under the vitaMedMD® and BocaGreenMD® brands.

We are a team of dedicated professionals with expertise in delivering medicines to the body through the inhaled route. The Leadership Team combined has over 100 years of experience in developing inhaled medicines and bringing these medicines to the U.S. and European markets. Our purpose at Transpire Bio is framed by two core elements: Access and Innovation. For common diseases where adequate therapies exist, we seek to expand access to these complex inhaled medicines globally by developing and commercializing lower-cost generic alternatives. For diseases with few treatment options, we seek to innovate by harnessing existing known mechanisms of action, and dramatically improve the risk-benefit profile of selected molecules by developing these as inhaled therapeutics. Our understanding of the complexities of inhaled drug-device products will allow us to advance these therapies and improve the health of people around the globe.

Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion deformities and related midfoot correction. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans1, of which Treace estimates 1.1 million are annual surgical candidates. Treace Medical has pioneered and patented the Lapiplasty® 3D Bunion Correction® system – a combination of instruments, implants, and surgical methods designed to surgically correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause2,3 of the bunion. At Treace Medical Concepts, Inc., our mission is to advance the standard of care for the surgical management of bunions and related midfoot deformities. Treace Medical offers the Adductoplasty® System, the Hammertoe PEEK Fixation System, the SpeedPlate™ System, and other ancillary The content herein is for informational purposes and intended for healthcare professionals only. Treace Medical Concepts, Inc. does not dispense medical advice. A surgeon should rely on his or her own professional clinical judgment when deciding whether to use a specific product when treating a particular patient. Prior to use of the device, the surgeon should refer to the instructions for use for complete indications, contraindications, warnings, and risks. Complete risk and benefit information: www.treace.com. Visit www.treace.com/privacy-policy for our Privacy Policy. Treace Medical will make an offer of employment only to individuals who have applied for a position using our official application. Be on alert for possible fraudulent offers of employment. Treace Medical will not solicit money or banking information from applicants. 1Nix S, et al. J Foot Ankle Res. 2010. 27:3:21. 2Dayton P, et al. J Foot Ankle Surg. 2016;55:567-71. 3Dayton P, et al. J Foot Ankle Surg. 2018;57:766-770.

Tregeutix (pronounced ti·rəˈgyoo·tiks or trəˈgyoo·tiks) is advancing unique, first-in-kind antigen-specific immunotherapeutic approaches by addressing how microbiota derived antigen cross-reactivity maintains full and complete repertoire of Foxp3+ regulatory T cells (Tregs) essential for health. Touted as a 'holy grail'​ for curing diseases such as allergy, autoimmunity and tumors since their 2001 discovery, thymus-derived Foxp3+ Tregs have yet to yield predictable therapeutic benefits in human trials. Much of this translational gap stems from a fundamental failure to recognize that Tregs rely on commensal microbiota derived antigen cross-reactivity to simultaneously coordinate both antigen-specific tolerance and effective immune response. At Tregeutix we are developing a novel discovery framework dubbed SPIRAL that predicts each and every Treg, regardless of its perceived antigen specificity, is maintained by microbiota derived cross-reactive antigens. Healthy microbiota is necessary for a healthy immune system. However, prevailing efforts to harness its therapeutic potential to treat inflammatory disorders are largely based on empirical correlations that lack predictability. In contrast, the novel discovery framework developed by Tregeutix, which relies on antigenic similarity (cross-reactivity), is uniquely positioned to identify specific microbiota necessary for individualized antigen-specific immunotherapy. By simplifying and removing unpredictability from antigen-specific immunotherapies, SPIRAL allows systematic and non-random discovery of novel class of Treg-based disease-modifying immunotherapeutics that we refer to as tregeutics, specific members of microbiota that maintain antigen-specific Tregs involved in protection against allergies and autoimmune diseases as well as in determining effectiveness of vaccines to natural infections and tumors.

TrippBio is a biotech company that identifies new applications for existing drugs as a way to treat viruses like SARS-CoV-2, which causes COVID-19.

Urica Therapeutics, Inc. (“Urica”) is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products to treat gout and other conditions associated with hyperuricemia. Urica acquired the rights to develop and commercialize Dotinurad, a potentially best-in-class URAT1 inhibitor, in the United States, United Kingdom, European Union, Canada, Middle East and North Africa (MENA) and Turkey from Fuji Yakuhin. Dotinurad has been approved to treat gout and hyperuricemia in Japan and is currently in a Phase 1 clinical trial in the United States. Urica was founded by Fortress Biotech, Inc. (Nasdaq: FBIO).

U.S. Stem Cell, Inc. is a leader in regenerative medicine and is committed to providing autologous cell therapies for the treatment of degenerative conditions. The company specializes in the development of proprietary, physician-based stem cell therapies; novel regenerative solutions, including its lead product AdipoCell™; physician training and certification; veterinary applications; stem cell banking; as well as creating and managing new stem cell clinics. In the past 20 years, to the company’s knowledge, U.S. Stem Cell, Inc. has completed more clinical treatments than any other regenerative care provider in the world. With more than 700 physicians trained and certified with the company, U.S. Stem Cell, Inc. boasts the largest network of physicians working together to continue its mission of harnessing the body’s own ability to heal from within to treat a wide variety of conditions and to improve quality of life.

U.S. Stem Cell, Inc. is a leader in regenerative medicine and is committed to providing autologous cell therapies for the treatment of degenerative conditions. The company specializes in the development of proprietary, physician-based stem cell therapies; novel regenerative solutions, including its lead product AdipoCell™; physician training and certification; veterinary applications; stem cell banking; as well as creating and managing new stem cell clinics. In the past 20 years, to the company’s knowledge, U.S. Stem Cell, Inc. has completed more clinical treatments than any other regenerative care provider in the world. With more than 700 physicians trained and certified with the company, U.S. Stem Cell, Inc. boasts the largest network of physicians working together to continue its mission of harnessing the body’s own ability to heal from within to treat a wide variety of conditions and to improve quality of life.

Veru is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancers. Our strategy is primarily to focus on the clinical development and commercialization of oncology drugs for the management of two of the most prevalent cancers globally – prostate cancer and breast cancer.

We are the regenerative medicine company that develops and delivers innovative allograft solutions designed to support the body’s healing and regenerative potential, ultimately improving patient outcomes and quality of life. The underpinnings of our regenerative medicine solutions technology date back 50 years to the founding of The University of Miami Tissue Bank in 1970. We experienced multiple firsts in clinical and scientific achievement leading up to 2014, when VIVEX acquired the University of Miami Tissue Bank. This acquisition streamlined our strategic plan to focus on new regenerative medicine solutions, research and development, expansion of manufacturing capabilities, and sales and marketing efforts.

Vycellix is a biopharmaceutical company developing novel platforms to optimize and enhance cell & gene based-therapies. The company's platforms include VY-UC to generate immune-privileged universal cells without altering the components that control self-recognition (HLA).

Vycor Medical was founded on this basic mission: "There must be a better way." - A better way to access surgical locations without unduly damaging surrounding tissue - A better way to perform less invasive critical procedures, minimizing collateral trauma and accelerating postoperative recovery Vycor Medical is committed to improving patient outcomes by making brain and spine surgery procedures safer and more effective. The ViewSite Brain Access System (VBAS) is an innovative device designed to optimize surgical retraction and access to sites within the brain, reduce damage to the surrounding tissue, and accelerate patient recovery. VYCOR MEDICAL® is a registered trademark of Vycor Medical, Inc. VIEWSITE™, VIEWSITE BRAIN ACCESS SYSTEM™, and VBAS™ are all common law trademarks of Vycor Medical, Inc.

Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com

Xēnix Medical is a surgical implant company focused on the development of novel science-based solutions for patients requiring spinal fusion surgery. The company, headquartered in Orlando, Florida, markets its line of spinal implant devices in the United States through a network of independent distributors.

Based in South Florida, ZEO ScientifiX™ is a publicly traded biotechnology company committed to the research, development and manufacture of new biologic medicine, with a focus on current and potential regenerative therapeutics. ZEO ScientifiX™ is the leading, fully integrated Biologic Medicine Company. Our mission is to transform regenerative medicine through the development of novel nano-technologies and to become the health care incubator for the next generation of biologic medicines.

We are a rare disease therapeutics company leading with science to make life-changing therapeutics available to patients with significant unmet needs. We involve key thought leaders, physicians, patients, care partners, and advocacy groups in all of our clinical and regulatory development strategies. With a keen understanding that drug development often requires creative solutions, we have the insight and expertise to forge new pathways to success that others have missed. By following the data without bias, our transparent narratives and common-sense perspective have successfully overcome complex development challenges to make much-needed therapies available to patients. Nimble and dauntless, we push boundaries beyond what is thought to be possible and advance new therapies that have the potential to bring meaningful improvement to patients’ lives.

ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging two licensed proprietary product platforms to develop pharmaceutical products that address unmet medical needs in the areas of renal and inflammatory diseases. Lead renal candidate, Phase 2a-ready VAR 200, mediates removal of excess intracellular lipids in the kidney’s filtration system that contribute to kidney damage leading to end-stage kidney disease. Lead anti-inflammatory drug candidate, inflammasome ASC inhibitor (IC 100), blocks initiation and perpetuation of damaging inflammation that’s pathogenic in a multitude of inflammatory diseases.